Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | The value of PD-L1 as a biomarker beyond lung cancers

Kevin Harrington • 27 Sep 2019
ESMO 2019
Head and Neck Cancer Pembrolizumab
KEYNOTE-048

Kevin Harrington, PhD, MBBS, Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK, explains to us the value of PD-L1 as a biomarker, focusing on head and neck squamous cell carcinoma. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Kevin Harrington

2:37
Challenges of combining SOC chemotherapy/radiotherapy and immunotherapy in head and neck cancer
Kevin Harrington • 16 Mar 2022
2:42
Recent advances in targeted therapy for head and neck cancer
Kevin Harrington • 16 Mar 2022
1:59
Potential of immunotherapy in head and neck cancer
Kevin Harrington • 16 Mar 2022
3:01
Update on oncolytic viruses for cancer treatment
Kevin Harrington • 27 Sep 2019

Related Videos

1:03
Challenges in implementing liquid biopsies for head and neck cancer
Mouadh Barbirou • 7 Apr 2024
2:43
Molecular profiling of tumor biomarkers in head and neck cancer
Mouadh Barbirou • 7 Apr 2024
1:40
The future of squamous cell carcinoma research at ESMO Asia 2023
Brian Henick • 6 Dec 2023
0:54
The role of immunotherapy in PD-L1 low advanced squamous cell carcinoma
Brian Henick • 6 Dec 2023
The content of VJOncology is intended for healthcare professionals